Statin Therapy and Risk of Fracture: Results From the JUPITER Randomized Clinical Trial
This analysis of the JUPITER trialled showed that rosuvastatin did not reduce fracture risk in the enrolled patients with elevated hs-CRP levels. Furthermore, higher baseline hs-CRP levels were nor associated with an increased risk of fractures in both groups.
:
Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality
The Pattern of Excess Cancer in Dialysis and Transplantation
Vitamins C and E to Prevent Complications of Pregnancy-Associated Hypertension
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Nephrology Clinical Trial Results Source Type: research
More News: Cancer | Cancer & Oncology | Cholesterol | Clinical Trials | Crestor | Dialysis | Hypertension | Kidney Transplant | Kidney Transplantation | Orthopaedics | Pregnancy | Rosuvastatin | Statin Therapy | Transplant Surgery | Transplants | Urology & Nephrology | Vitamins